2023 'Medical Innovation Pioneers, Changing the World' BD Medical + HiMed MedTech Innovation Fellowship Prospectus

The 2023 BD + HiMed Medical Innovation Camp, themed “Medical Pioneers, Changing the World,” will officially launch in September 2023, organized byBD, a global industry leader, leverages HiMed Yanxi’s localized innovation resources, supported by world-leading laboratory equipment and simulation environments., in conjunction with the Stanford Biodesign scientific innovation process framework, committed to jointlyCultivating Localized Innovative Technologies and Products in Medical Devices. Join us!

Areas of Focus:Interventional Oncology,Hemodialysis,Urology, with a focus on lung tumors, breast tumors, vascular access disorders, and urolithiasis.and related complications.

Technologies to Watch:Ablation Therapy, Minimally Invasive Intervention/Implantation, New Materials, Monitoring Systemsemerging technologies and new directions.

- Physicians, engineers, academic researchers, entrepreneurs, and business professionals;

- At least 3 years of work and R&D experience in related fields;

- Possess an innovative spirit and a strong sense of teamwork, with a willingness to devote personal time to the journey of innovation.

Objective:Through innovative training, brainstorming, in-depth clinical immersion, and experimental validation, gain a comprehensive understanding of the Biodesign medical technology innovation framework, immerse yourself in an innovative atmosphere, and spark creative ideas.

Time:September 2023 – January 2024 (Weekends)

Location:Shanghai · Zhangjiang Science City

August–September 15

Recruitment and Confirmation

September 23–24

2-Day Mandatory Training (30 Participants)

Late September

Fellow Program Enrollment (8–12 participants)

October–January

Biodesign Innovation Journey

January

Demo Day Graduation Pitch

Scan or recognize the QR code below to register.

Contact Person:

Xiao Mai: 19916567386 (Mobile/WeChat)

Teacher Huang: 13795377664 (Mobile/WeChat)

Professor Song Chengli, Chief Scientist & Senior Gold Mentor of the HiMed Platform

Professor, Doctoral Supervisor, Oriental Scholar, and Official Chinese Translator for Biodesign. He holds a Ph.D. in Mechanical Engineering from Cardiff University, UK, and serves as a Visiting Research Fellow at the University of Dundee. Upon returning to China, he joined the School of Medical Devices and Food at the University of Shanghai for Science and Technology, where he oversees the work of the Ministry of Education’s Engineering Research Center for Modern Minimally Invasive Medical Devices and Technologies, serving as its Executive Deputy Director. He has successfully incubated multiple medical innovation projects and secured financing for them.

BD-HiMed Joint Medical Innovation Acceleration Platform is equipped with globally leading laboratory equipment and simulation environments, serving as an innovative space that integrates clinical practice and engineering. In the future, it will empower BD’s partners and assist clinical experts in translating scientific research achievements into practical applications. Meanwhile, leveraging multidisciplinary training programs offered by the training center, the platform facilitates close interaction between clinical experts and engineering teams, enabling R&D teams to promptly and thoroughly grasp clinical feedback. This enhances the efficiency and quality of product development, fosters more source-innovative solutions, and better serves local market demands.

As one of the world’s leading medical technology companies, BD (Becton, Dickinson and Company) is dedicated to innovative solutions that improve quality of life and clinical diagnostics. Its business spans chronic disease management, cancer diagnosis and treatment, infectious disease prevention and control, and life sciences. By enhancing methods of medical discovery, diagnostic efficacy, and quality of care, BD leads global health advancement. Founded in New York in 1897 and headquartered in Franklin Lakes, New Jersey, USA, the company operates worldwide and employs more than 4,000 people in China.

HiMed, jointly initiated by Yanxitang—a national-level enterprise technology incubator—and over 30 partners from the medical industry, investment sector, universities, and research institutions, integrates investment, incubation, and acceleration services. It is committed to building the leading brand in the early-stage medical innovation field. Its portfolio includes brands such as the HiMed Medical Innovators Community, HiMed InnoHub Innovation Center, HiMed International Medical Innovation Center, and HiMed Angel Fund, providing one-stop incubation and acceleration services for high-quality medical projects from both domestic and international markets, guiding them from concept to launch.Yanxitang Incubator is a well-established incubator in the biomedical field, located in Zhangjiang Science City, Shanghai. It operates four innovation bases with a total incubation area of 20,000 square meters. In 2016, it was awarded the title of “National-Level Enterprise Technology Incubator” (Document No. [2016] 418 issued by the Ministry of Science and Technology).